IFRX

Business Context and Reporting Period

This Form 6-K filing by InflaRx N.V. covers the period of January 2026, specifically referencing a press release issued on January 8, 2026. The Company, a biopharmaceutical firm based in Jena, Germany, announced a strategic pivot focused on capital-efficient execution. The primary objective is to extend the cash runway and realign resources toward the development of izicopan for hidradenitis suppurativa and other inflammation indications, positioning it as a potential best-in-class C5aR inhibitor.

Key Financial Metrics

The filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period. However, it discloses the following financial impacts related to the strategic restructuring:

• One-Time Charge: Approximately $7 million estimated charge resulting from restructuring activities.
• Charge Composition: The majority of the charge is non-cash, related to the write-off of vilobelimab (Gohibic) inventory. A smaller portion covers personnel-related costs and contract terminations.
• Cash Runway: Management expects these measures to extend the cash runway to mid-2027.
• Debt and Liquidity: The filing text does not provide clear values for total debt or current liquidity positions.

Material Changes Versus Prior Period

The Company has initiated significant operational changes compared to its prior strategy:

• Workforce Reduction: A reduction of approximately 30% of the workforce has been initiated.
• Commercial Spending: Substantial reductions in commercial spending and related functions for Gohibic (vilobelimab) have been implemented.
• Strategic Focus: A shift away from broad commercialization of vilobelimab toward a "pipeline-in-a-product" approach centered on izicopan, while maintaining limited reactive supply capabilities for Gohibic under Emergency Use Authorization (EUA).

Guidance, Outlook, and Risks

Outlook and Management Commentary:

• The Company anticipates a significantly leaner cost structure enabling sustained reductions in operating expenses.
• Operational capability for the BARDA "Just Breathe" Phase 2 clinical platform study in ARDS will be maintained without negative impact.
• Gohibic will remain available for ordering in the U.S. on a reactive basis.
• The Company will continue to review partnering opportunities for Gohibic in the U.S. and Europe.
• A meeting with the U.S. FDA is anticipated to determine a development path for vilobelimab in pyoderma gangrenosum, likely requiring a partner.

• The filing includes standard forward-looking statement disclaimers regarding risks, uncertainties, and factors that may cause actual results to differ materially from projections.
• Success in extending the cash runway and achieving value creation depends on the successful execution of cost-cutting measures and potential future partnerships.

Investor Verification Checklist

• Verify the exact composition of the $7 million one-time charge between non-cash inventory write-offs and cash restructuring costs.
• Confirm the current cash balance and burn rate to validate the projected mid-2027 cash runway.
• Monitor progress on the FDA meeting regarding vilobelimab in pyoderma gangrenosum and the status of potential partnership discussions.
• Assess the impact of the 30% workforce reduction on the timeline for the izicopan development program.
• Review the status of the BARDA "Just Breathe" Phase 2 study to ensure no delays have occurred due to restructuring.